Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
药物研究 酶学 囊泡 肿瘤 内分泌与代谢疾病
/
经典阳性药
小分子阳性药 酶制剂 免疫/炎症 酶抑制剂 其他抑制剂/激动剂 NF-κB 帕金森与阿尔茨海默症 肿瘤干细胞 Toll样受体 PPAR Signaling Pathway Wnt Signaling Pathway 细胞焦亡 胰腺癌 衰老 宫颈癌
/
消化系统
环氧合酶 抗炎 IKK NF-κB IL 环氧合酶抑制剂
/ 5-Aminosalicylic Acid/5-氨基水杨酸

5-Aminosalicylic Acid/5-氨基水杨酸 {[allProObj[0].p_purity_real_show]}

货号：A105320 同义名： 5-氨基-2-羟基苯甲酸 / Mesalamine; 5-ASA

5-Aminosalicylic Acid 是一种 IL-1β 生成抑制剂和 PPARγ 激动剂，可抑制 PAK1 和 NF-κB 活性，广泛用于炎症性肠病相关免疫调控研究。

5-Aminosalicylic Acid/5-氨基水杨酸 化学结构 CAS号：89-57-6
5-Aminosalicylic Acid/5-氨基水杨酸 化学结构
CAS号：89-57-6
5-Aminosalicylic Acid/5-氨基水杨酸 3D分子结构
CAS号：89-57-6
5-Aminosalicylic Acid/5-氨基水杨酸 化学结构 CAS号：89-57-6
5-Aminosalicylic Acid/5-氨基水杨酸 3D分子结构 CAS号：89-57-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

5-Aminosalicylic Acid/5-氨基水杨酸 纯度/质量文件 产品仅供科研

货号：A105320 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 NF-κB ↓ 其他靶点 纯度
Ammonium pyrrolidine-1-carbodithioate ✔ 98%
QNZ ++++

NF-κB, IC50: 11 nM

 		99%+
Sodium 4-Aminosalicylate Dihydrate ✔ 98%
Sodium Salicylate ✔ 95%
Parthenolide ✔ p53 97% HPLC
JSH-23 +

NF-κB, IC50: 7.1 μM

 		98%
Phenethyl caffeate ✔ 98%
Andrographolide ✔ 98+%
Curcumin ✔ Nrf2,HDAC 98%
SC75741 +++

NF-κB, EC50: 200 nM

 		99%+
CBL0137 HCl ++

NF-κB, EC50: 0.47 μM

 		p53 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

5-Aminosalicylic Acid/5-氨基水杨酸 生物活性

描述 F-5-Aminosalicylic acid (5-ASA) is a specific agonist for PPARγ, and only PPARγ but not PPARα or PPARδ induces p65 degradation. 5-Aminosalicylic acid induces degradation of p65 protein indicative of PPARγ's E3 ubiquitin ligase activity. 5-Aminosalicylic acid blocks NF-κB in intestinal epithelial cells (IECs) through inhibition of PAK1[3]. Pretreatment with 5-Aminosalicylic acid (5-ASA) or Nimesulide at different concentration (10-1000 μmol/L) for 12-96 h, inhibits the growth of HT-29 colon carcinoma cells in a dose and time-dependent manner. Combined 5-Aminosalicylic acid (final concentration 100 μM) and Nimesulide (final concentration 10-1000 μM) inhibits the proliferation of HT-29 colon carcinoma cells in a dose-dependent manner, being more potent than corresponding dose of Nimesulide. In A/JOlaHsd mice, 5-ASA suppressed colon carcinogenesis by decreasing the number of aberrant crypt foci (75%) and aberrant crypts (22%) induced by AOM (azoxymethane) treatment with an absence of 5-ASA response after GW9662 administration[4]. Pretreatment with 5-ASA or nimesulide at the concentration of 10-1000 micromol/L inhibited proliferation of HT-29 colon carcinoma cells in a dose-dependent manner in vitro. The inhibition rate of HT-29 colon carcinoma cell proliferation was also increased when pretreated with 5-ASA (100 micromol/L) or nimesulide (100 micromol/L) for 12-96 h, which showed an obvious time-effect relationship. 5-ASA and nimesulide may inhibit the proliferation of HT-29 colon carcinoma cells and coadministration of these agents may have additional chemopreventive potential[5].

5-Aminosalicylic Acid/5-氨基水杨酸 细胞实验

Cell Line
Concentration Treated Time Description References
HT-29 colon carcinoma cells 10-1000 µM 12-96 hours 5-Aminosalicylic acid and nimesulide alone or in combination inhibited the proliferation of HT-29 colon carcinoma cells and promoted apoptosis in a dose- and time-dependent manner. World J Gastroenterol. 2007 May 28;13(20):2872-7.
RAW 264.7 macrophages 0-5 mg/mL 24 hours Evaluate cytotoxicity of P2 and P3, showing minimal toxicity at the highest tested concentration J Nanobiotechnology. 2024 Aug 6;22(1):468.
Caco-2 cells 0-5 mg/mL 24 hours Evaluate cytotoxicity of P2 and P3, showing minimal toxicity at the highest tested concentration J Nanobiotechnology. 2024 Aug 6;22(1):468.
S/RG/C2 20-40 mM 24, 48, 72 hours 5-ASA significantly inhibited the growth of adenoma cells and reduced the number of attached cells. Br J Cancer. 2021 Jun;124(12):1959-1969.
PC/AA/C1 20-40 mM 24, 48, 72 hours 5-ASA inhibited the growth of adenoma cells and significantly reduced the number of attached cells. At 40 mM, significant induction of cell death was observed after 72 hours. Br J Cancer. 2021 Jun;124(12):1959-1969.
Human neutrophils 0.005, 0.25, 0.5 mM 30 minutes To evaluate the inhibitory effect of 5-aminosalicylic acid on PMA-induced ROS production and NET formation in human neutrophils. Results showed that 5-aminosalicylic acid significantly inhibited ROS production and NET formation. Mediators Inflamm. 2013;2013:710239.
Human primary chondrocytes 10 µM 48 hours 5-ASA inhibits IL-1β and COLpep-induced upregulation of OSCAR protein expression Nat Commun. 2024 Feb 3;15(1):1024.
Mouse primary chondrocytes 10 µM 48 hours 5-ASA inhibits COLpep-induced upregulation of OSCAR expression and downregulates COX-2 and LOX-5 expression Nat Commun. 2024 Feb 3;15(1):1024.
3T3-L1 preadipocytes 100 µM-10 mM 8 days To evaluate the effect of 5-ASA on the differentiation of 3T3-L1 preadipocytes, results showed that 5-ASA significantly promoted adipocyte differentiation. J Exp Med. 2005 Apr 18;201(8):1205-15.

5-Aminosalicylic Acid/5-氨基水杨酸 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Abca4−/−Rdh8−/− mice Light-induced retinal degeneration model Intraperitoneal injection 0.5 mg and 1.0 mg Single administration, evaluated 7 days later Evaluate the protective effect of nanoglobular 5-ASA conjugate against light-induced retinal degeneration. Results showed that the conjugate provided more effective 7-day protection at a reduced dose compared to free 5-ASA. ACS Nano. 2014 Jan 28;8(1):153-61
C57BL/6 J mice Surgery-induced medial-meniscus destabilization (DMM) model Intra-articular injections 0.5, 1, or 2 mg/kg Once weekly for 8 weeks 5-ASA significantly ameliorates DMM-induced OA, including reduced articular cartilage erosion, osteophyte formation, and synovitis Nat Commun. 2024 Feb 3;15(1):1024.
129/Sv mice TNBS-induced colitis model Oral 100 mg/kg Once daily for 5 days To evaluate the therapeutic effect of 5-ASA on TNBS-induced colitis, results showed that 5-ASA significantly reduced colonic inflammation. J Exp Med. 2005 Apr 18;201(8):1205-15.
BALB/c mice DSS-induced colitis model Intragastric administration 100 mg/kg Once daily for 1 week 5-ASA ameliorated DSS-induced colitis symptoms in mice by modulating gut microbiota and bile acid metabolism, including increased body weight gain and colon length, and decreased disease activity index (DAI) score and spleen index. Cell Mol Life Sci. 2022 Aug 1;79(8):460
C57BL/6N mice DSS-induced ulcerative colitis model Enema injection 200 mg/kg Once daily for 14 days Simultaneous treatment of 5-aminosalicylic acid and treadmill exercise improved histological damage, increased body weight, colon weight, and colon length, and decreased the disease activity index score and collagen deposition by inhibiting NF-κB/MAPK signaling pathway activation. Int J Mol Sci. 2024 May 7;25(10):5076
C57BL/6J mice DSS-induced colitis model Oral gavage 300 mg/kg Once daily for 7 days Evaluate therapeutic efficacy of P3 in DSS-induced colitis, showing significant reduction in weight loss, DAI, colon shortening, and inflammatory markers J Nanobiotechnology. 2024 Aug 6;22(1):468.
C57BL/6 mice DSS-induced colitis model Oral gavage 75 mg/kg Once daily for 7 days Evaluation of the therapeutic effect of 5-ASA in colitis, showing significant restoration of colon length and reduction in MPO activity in NAT KO mice Inflamm Bowel Dis. 2016 Aug;22(8):1793-802
C57BL/6 mice DSS-induced colitis model Oral 820 mg/kg Once daily for 4 weeks To investigate the effect of 5-aminosalicylic acid on gut microbiota and its protective effect against colitis. Results showed that 5-ASA altered the gut microbiota composition, increasing the abundance of Firmicutes and Actinobacteria while decreasing Bacteroidetes. Additionally, 5-ASA-treated mice exhibited lower disease activity index and milder inflammatory responses in DSS-induced colitis. Sci Rep. 2023 Jul 28;13(1):12241

5-Aminosalicylic Acid/5-氨基水杨酸 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00746447 Colitis, Ulcerative ... 展开 >> Recurrence 收起 << Phase 3 Completed - Germany ... 展开 >> Evangelisches Krankenhaus Kalk, Medical Dept. Cologne, Germany, 51103 收起 <<
NCT01699438 Irritable Bowel Syndrome Phase 2 Completed - Sweden ... 展开 >> Sahlgrenska University Hospital Göteborg, Sweden Karolinska University Hospital Huddinge, Sweden Norrland's University Hospital Umeå, Sweden 收起 <<
NCT01257399 Ulcerative Colitis in Remissio... 展开 >>n 收起 << Phase 3 Completed - China ... 展开 >> Shanghai Hospital Shanghai, China 收起 <<

5-Aminosalicylic Acid/5-氨基水杨酸 参考文献

[1]Khare V, Lyakhovich A, et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol. 2013 Jan 15;85(2):234-44.

[2]Egan LJ, Mays DC, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999 Sep 10;274(37):26448-53.

[3]Dammann K, Khare V, Lang M, Claudel T, Harpain F, Granofszky N, Evstatiev R, Williams JM, Pritchard DM, Watson A, Gasche C. PAK1 modulates a PPARγ/NF-κB cascade in intestinal inflammation. Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2349-60

[4]Rousseaux C, El-Jamal N, Fumery M, Dubuquoy C, Romano O, Chatelain D, Langlois A, Bertin B, Buob D, Colombel JF, Cortot A, Desreumaux P, Dubuquoy L. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγ. Carcinogenesis. 2013 Nov;34(11):2580-6

[5]Fang HM, Mei Q, Xu JM, Ma WJ. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol. 2007 May 28;13(20):2872-7

5-Aminosalicylic Acid/5-氨基水杨酸 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.53mL

1.31mL

0.65mL

32.65mL

6.53mL

3.26mL

65.30mL

13.06mL

6.53mL

5-Aminosalicylic Acid/5-氨基水杨酸 技术信息

CAS号89-57-6
分子式C7H7NO3
分子量 153.14
SMILES Code C1=C(N)C=CC(=C1C(O)=O)O
MDL No. MFCD00007877
别名 5-氨基-2-羟基苯甲酸 ;Mesalamine; 5-ASA; MAX-002; AJG-501; Z-206; Asacol; Mesalazine
运输蓝冰
InChI Key KBOPZPXVLCULAV-UHFFFAOYSA-N
Pubchem ID 4075
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, room temperature
溶解方案

DMSO: 65 mg/mL(424.46 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一
方案 二

Tags: 5-Aminosalicylic Acid | Mesalamine;5-ASA;MAX-002;AJG-501;Z-206;Asacol;Mesalazine | 5-氨基-2-羟基苯甲酸 | Digestive System | Anti-inflammation | Cyclooxygenase (COX) | Cyclooxygenase (COX) Inhibitor | NF-κB | IKK | IL | AmBeed-信号通路专用抑制剂 | 5-Aminosalicylic Acid/5-氨基水杨酸 纯度/质量文件 | 5-Aminosalicylic Acid/5-氨基水杨酸 亚型比较 | 5-Aminosalicylic Acid/5-氨基水杨酸 生物活性 | 5-Aminosalicylic Acid/5-氨基水杨酸 临床数据 | 5-Aminosalicylic Acid/5-氨基水杨酸 参考文献 | 5-Aminosalicylic Acid/5-氨基水杨酸 实验方案 | 5-Aminosalicylic Acid/5-氨基水杨酸 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z